• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sangamo Therapeutics Inc.

    8/8/25 4:27:13 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email
    S-8 1 d933616ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 8, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SANGAMO THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   68-0359556

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    501 Canal Blvd.

    Richmond, California

      94084
    (Address of Principal Executive Offices)   (Zip Code)

    Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan

    (Full Title of Plans)

    Alexander D. Macrae

    President and Chief Executive Officer

    Sangamo Therapeutics, Inc.

    501 Canal Blvd.

    Richmond, California 94084

    (510) 970-6000

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

     

     

    Copies to:

     

    Scott B. Willoughby

    Chief Legal Officer and Corporate Secretary

    Sangamo Therapeutics, Inc.

    501 Canal Blvd.

    Richmond, California 94804

    (510) 970-6000

     

    Chadwick L. Mills

    Courtney M.W. Tygesson

    Cooley LLP

    3 Embarcadero Center, 20th Floor

    San Francisco, California 94111

    (415) 693-2000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by Sangamo Therapeutics, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 14,000,000 shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”), to be issued pursuant to the Registrant’s Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”). The Registrant previously registered (i) 19,131,725 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-225552) filed with the Commission on June 11, 2018 (the “2018 Form S-8”), (ii) 9,900,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-241033) filed with the Commission on August 5, 2020 (the “2020 Form S-8”), (iii) 7,900,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-269925) filed with the Commission on February 23, 2023 (the “February 2023 Form S-8”), (iv) 10,000,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-273805) filed with the Commission on August 8, 2023 (the “August 2023 Form S-8”), and (v) 11,000,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-283180) filed with the Commission on November 12, 2024 (together with the 2018 Form S-8, the 2020 Form S-8, the February 2023 Form S-8 and the August 2023 Form S-8, the “Prior Registration Statements”). This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

      •  

    the Registrant’s annual report on Form 10-K for the year ended December 31, 2024, which was filed with the Commission on March 17, 2025;

     

      •  

    the information specifically incorporated by reference into the Registrant’s annual report on Form 10-K for the year ended December 31, 2024 from the Registrant’s definitive proxy statement on Schedule 14A, which was filed with the SEC on  April 30, 2025;

     

      •  

    the Registrant’s quarterly reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, which were filed with the Commission on May 12, 2025 and August 7, 2025, respectively;

     

      •  

    the Registrant’s current reports on Form 8-K, which were filed with the Commission on February  6, 2025, May  6, 2025, May  13, 2025, June  16, 2025 and June 24, 2025; and


      •  

    the description of the Common Stock contained in the Registrant’s registration statement on Form 8-A, which was filed with the Commission on March  31, 2000, including all amendments and reports filed for the purpose of updating such description, including Exhibit 4.1 of the Registrant’s annual report on Form 10-K for the year ended December 31, 2024.

    All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    Item 8.

    Exhibits.

    Exhibit Index

     

    Exhibit
    No.
      

    Description

     3.1    Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).
     3.2    Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 5, 2024).
     3.3    Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed December 19, 2022).
     5.1    Opinion of Cooley LLP.
    23.1    Consent of Independent Registered Public Accounting Firm.
    23.2    Consent of Cooley LLP (included in Exhibit No. 5.1).
    24.1    Power of Attorney (included on signature page to this Registration Statement).
    99.1    Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 16, 2025)
    107    Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Richmond, State of California, on August 8, 2025.

     

    SANGAMO THERAPEUTICS, INC.
    By:   /s/ Alexander D. Macrae

    Name:

     

    Alexander D. Macrae, M.B., Ch.B., Ph.D.

    Title:

     

    President and Chief Executive Officer

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander D. Macrae, Prathyusha Duraibabu and Scott Willoughby, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Alexander D. Macrae

    Alexander D. Macrae, M.B., Ch.B., Ph.D.

       President, Chief Executive Officer and Director
    (Principal Executive Officer)
      August 8, 2025

    /s/ Prathyusha Duraibabu

    Prathyusha Duraibabu

       Senior Vice President and Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)
      August 8, 2025

    /s/ H. Stewart Parker

    H. Stewart Parker

       Chair of the Board   August 8, 2025

    /s/ Courtney Beers

    Courtney Beers, Ph.D.

       Director   August 8, 2025


    /s/ Robert F. Carey

    Robert F. Carey

       Director   August 8, 2025

    /s/ Kenneth J. Hillan

    Kenneth J. Hillan, M.B., Ch.B.

       Director   August 8, 2025

    /s/ Margaret A. Horn

    Margaret A. Horn, J.D.

       Director   August 8, 2025

    /s/ John H. Markels

    John H. Markels, Ph.D.

       Director   August 8, 2025

    /s/ James R. Meyers

    James R. Meyers

       Director   August 8, 2025

    /s/ Karen L. Smith

    Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.

       Director   August 8, 2025
    Get the next $SGMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 746,279 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    7/24/25 4:59:23 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,191,460 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    7/24/25 4:58:36 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 749,677 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    7/24/25 4:57:27 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SGMO
    SEC Filings

    View All

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

    Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticipated in late 2026. Held productive meeting with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submissi

    8/7/25 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

    RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be

    7/31/25 4:05:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

    STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval Isaralgagene civaparvovec showed a favorable safety and tolerability profile Sangamo intends to submit a Biologics License Application (BLA) in 2026 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry diseas

    6/24/25 8:05:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Sangamo Therapeutics Inc.

    S-8 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    8/8/25 4:27:13 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Sangamo Therapeutics Inc.

    10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    8/7/25 4:05:16 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    8/7/25 4:02:57 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics upgraded by Truist with a new price target

    Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

    12/13/24 8:18:20 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

    12/10/24 11:58:57 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

    11/3/23 7:45:03 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Financials

    Live finance-specific insights

    View All

    Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

    Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticipated in late 2026. Held productive meeting with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submissi

    8/7/25 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

    RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be

    7/31/25 4:05:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web

    5/12/25 4:00:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    11/12/24 4:53:35 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    11/4/24 1:54:32 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    8/16/24 6:40:25 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Leadership Updates

    Live Leadership Updates

    View All

    Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

    5/16/23 8:00:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

    CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

    11/22/21 7:00:00 AM ET
    $ORGO
    $PACB
    $SGMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

    5/24/21 4:15:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care